Global Cardiovascular Drugs industry

• Publication date: April 2010

This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others. The report provides separate comprehensive analytics for...

This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 115 companies including many key and niche players such as Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Biovail Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Forest Laboratories, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Global Drug And Medication Industry

CARDIOVASCULAR DRUGS MCP-1698
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
ACE Inhibitors I-4
Angiotensin II Receptor Blockers I-4
Antiarrhythmics I-4
Antithrombotics (Anticoagulants and Antiplatelets) I-4
Beta Blockers I-5
Calcium Channel Blockers I-5
Cholesterol Reducing Drugs I-5
Others I-5


II. EXECUTIVE SUMMARY

1. CARDIOVASCULAR DRUGS REVIEW II-1
Cardiovascular Disease - The Undying Challenge II-1
World Pharmaceutical Market and Cardiovascular Drugs Dominance II-1
Table 1: World Pharmaceutical Market - Leading Pharmaceutical
Companies Ranked by Global Sales and their Leading Product
(in US$ Million): 2008 (includes corresponding Graph/Chart) II-2

Table 2: World Pharmaceutical Research & Development -
Leading Pharmaceutical Companies Ranked in Order of
Pharmaceutical R&D Investment (in US$ million): 2008
(includes corresponding Graph/Chart) II-3
World Cardiovascular Drugs Market II-4
Table 3: World Cardiovascular Drugs Market - Value Sales of
Leading Drugs: 2008 (includes corresponding Graph/Chart) II-5

Table 4: Select Leading Myocardial Infarction Drugs
Worldwide: Value Sales for 2007 and 2008 in US$ Million II-6

Table 5: Select Leading Coronary Artery Disease/
Atherosclerosis Drugs Worldwide: Value Sales for 2007 and
2008 in US$ Million II-6

Table 6: Select Leading Congestive Heart Failure Drugs
Worldwide: Value Sales for 2007 and 2008 in US$ Million II-6

Table 7: Select Leading Angina Drugs Worldwide: Value Sales
for 2007 and 2008 in US$ Million II-6
Table 8: Estimated Number of Products Available for Select
Cardiovascular Indications (includes corresponding Graph/
Chart) II-7
Cardiovascular Drug Categories At A Glance II-7
Antihypertensives II-7
Antihyperlipidemics II-7
Anticoagulants II-8
Antiplatelets II-8
Growth Drivers / Market Accelerators II-8
Combination Products II-8
Drug Delivery Technologies II-8
Growth Inhibitors / Market Challengers II-9
Patent Expiry of Best Selling Products II-9
List of Leading Cardiovascular Drugs with Upcoming Patent
Expiries II-9
Lack of Product Differentiation II-10
Fewer Product Introductions II-10
Growing Health Care Expenditure II-10
World Cardiovascular Drugs Market Outlook II-10
Cardiovascular Drugs Market - Current & Future Analysis II-10
By Geographic Region II-10
By Drug Class II-11
Cholesterol Reducing Drugs Lead the Way II-11
Angiotensin II Receptor Blockers - The Second Largest Drug
Category II-11
Antithrombotics - An Active Area of Reasearch and Development II-11

2. MARKET DYNAMICS II-12
United States and Europe - Far Ahead and Far More Powerful II-12
Anticoagulants - Remarkable Drug Development Potential II-12
Anticoagulants to Lose UA/AMI Indications to Antiplatelets II-12
Novel Anticoagulants to Drive Atrial Fibrillation Drug Market II-13
Lack of R&D Innovation, Genericization Characterize the
Antihypertensives Category II-13
Protein Therapy Research Promises Cardiovascular Disease
Treatment II-14

3. AN OVERVIEW OF CARDIOVASCULAR DISEASES II-15
Cardiovascular Disease - Description II-15
Atherosclerosis - Leading Cause of Cardiovascular Disease II-15
An Insight into the Risk Factors II-15
Controllable Risk Factors II-16
High Blood Cholesterol II-16
HDL Cholesterol II-16
HDL Cholesterol Levels and Potential Risk of
Cardiovascular Disease II-16
LDL Cholesterol II-16
LDL Cholesterol Levels and Potential Risk of
Cardiovascular Disease II-17
Triglyceride Levels II-17
Triglyceride Level and Potential Risk of Cardiovascular
Disease II-17
High Blood Pressure II-17
Obesity II-18
Smoking II-18
Uncontrollable Risk Factors II-18
Age II-18
Gender II-18
Heredity / Ethnicity II-19
Diabetes II-19
Other Risk Factors II-19
Stress II-19
Alcohol II-19
Sedentary Lifestyle/ Physical Inactivity II-19
Diseases of the Heart II-20
Angina II-20
Causes and Symptoms II-20
Treatment with Drugs II-20
Cardiac Arrest II-20
Causes and Symptoms II-21
Cardiomyopathy II-21
Ischemic Cardiomyopathy II-21
Non-ischemic Cardiomyopathies II-21
Arrhythmogenic Right Ventricular Dysplasia II-22
Causes and Symptoms II-22
Treatment with Drugs II-23
List of Drugs Used for the Treatment of Ischemic
Cardiomyopathy, Non-ischemic Cardiomyopathies (
Hypertrophic, Dilated and Restrictive), and
Arrhythmogenic Right Ventricular Dysplasia II-23
Congestive Heart Failure II-24
Heart Failure Classification as per the NYHA and ACC/AHA II-24
Table 9: Prevalence Rates of Congestive Heart Failure in
Select Countries (per 10,000) (includes corresponding
Graph/Chart) II-24
Causes and Symptoms II-25
List of Causes of Left Side and Right Side Heart Failure II-25
Treatment with Drugs II-26
ACE Inhibitors II-26
Aldosterone Blockers II-26
Angiotensin II Receptor Blockers II-26
Beta-blockers II-26
Diuretics II-26
Coronary Artery Disease II-27
Causes and Symptoms II-27
Treatment with Drugs II-27
Myocardial Infarction II-28
Causes and Symptoms II-28
Treatment with Drugs II-29
Congenital Heart Disease II-29
Cyanotic and Non-cyanotic Congenital Heart Disease II-29
Causes and Symptoms II-29
Treatment with Drugs II-30
Beta-blockers II-30
Calcium Channel Blockers II-30
Angiotensin II Receptor Blockers II-30
ACE Inhibitors II-31
Diuretics II-31
Pericardial Disease II-31
Causes and Symptoms II-31
Valvular Heart Disease II-31
Causes and Symptoms II-32
Diseases of the Blood Vessels II-32
Aneurysm II-32
Causes and Symptoms II-33
Different Types of Aneurysm and their Signs and Symptoms II-33
Atherosclerosis & Arteriosclerosis II-34
Causes and Symptoms II-34
Treatment with Drugs II-35
Statins II-35
Antiplatelets II-35
Anticoagulants II-35
Antihypertensives II-35
Hypertension II-35
Blood Pressure Levels (in adults aged 18 and above) and Risk
of Cardiovascular Disease II-36
Primary Hypertension II-36
Secondary Hypertension II-36
Causes and Symptoms II-37
Treatment with Drugs II-37
Lymphedema II-37
Causes and Symptoms II-38
Treatment with Drugs II-38
Peripheral Arterial Disease II-38
Causes and Symptoms II-38
Treatment with Drugs II-39
Stroke II-39
Types of Ischemic Strokes and Hemorrhagic Strokes and their
Description II-40
Causes and Symptoms II-40
Treatment with Drugs II-40
Vasculitis II-41
Causes and Symptoms II-41
Treatment with Drugs II-41

4. A REVIEW OF CARDIOVASCULAR DRUGS II-42
Adrenergic Blockers II-42
Indications for Cardiovascular Diseases: II-42
List of Indications for Different Types of Alpha-blockers II-43
List of Indications for Different Types of Beta-blockers II-43
Angiotensin Converting Enzyme Inhibitors II-43
List of Different Types of ACE Inhibitors and Products II-44
Indications for Cardiovascular Diseases: II-44
Angiotensin II Receptor Antagonists II-44
List of Different Types of Angiotensin II Receptor
Antagonists and Products II-45
Indications for Cardiovascular Diseases: II-45
Anticoagulants II-45
Anticoagulant Drug Classes II-46
Oral Anticoagulants II-46
Warfarin II-46
Coumadin II-46
Injectable Anticoagulants II-47
Heparin II-47
Unfractionated Heparin II-48
Low Molecular Weight Heparin II-48
Indications for Cardiovascular Diseases: II-49
Antiarrhythmics II-49
List of Different Types of Antiarrhythmic Drugs and Products II-50
Antihyperlipidemics II-50
Indications for Cardiovascular Diseases: II-51
Antiplatelets II-51
Indications for Cardiovascular Diseases: II-52
List of Indications for Select Antiplatelet Drugs II-52
Calcium Channel Blockers II-52
Indications for Cardiovascular Diseases: II-52
List of Indications for Select Calcium Channel Blockers II-53
Diuretics II-53
List of Different Classes and Types of Diuretics II-54
Indications for Cardiovascular Diseases: II-54
Thrombolytics II-55
Indications for Cardiovascular Diseases: II-55
Vasodilators II-55
List of Types of Vasodilators and Brand Names II-56
Others II-56

5. CARDIOVASCULAR PIPELINE II-57
Table 10: Estimated Number of Candidates in Development Phase
by Select Cardiovascular Indication (includes corresponding
Graph/Chart) II-57

Table 11: Estimated Number of Pipeline Products by Select
Cardiovascular Indication (includes corresponding Graph/Chart) II-58
Cardiovascular Pipeline Phase III II-58
List of Cardiovascular Pipeline Products in Phase III
Development (as of March 2007) II-58
Cardiovascular Pipeline Phase II II-60
List of Cardiovascular Pipeline Products in Phase II
Development (as of March 2007) II-60
Cardiovascular Pipeline Phase I II-62
List of Cardiovascular Pipeline Products in Phase I
Development (as of March 2007) II-62
Cardiovascular Pipeline Preclinical Development II-64
List of Cardiovascular Pipeline Products in Preclinical
Development (as of March 2007) II-64

6. RESEARCH & DEVELOPMENT II-67
Sanofi-aventis and BMS Announce Results of ACTIVE A Phase III
Study II-67
Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan II-67
China Pharma Commences Clinical Trials for Candesartan Generic II-67
Gilead Sciences Announces Phase III Results of Ambrisentan II-67
Taipei Medical University Reveals Results of New Blood
Pressure Study II-68
Researchers Identify New Genes Affecting Blood Pressure II-68
Italian Study Demonstrates Benefits of Investigational
Amlodipine and Telmisartan Combination Treatment in Blood
Pressure Patients Exposed to Risk of Cardiovascular Events II-68
Gilead Sciences Announces Phase III Darusentan Data II-69
Gilead Sciences Commences Phase II Trial of Cicletanine II-69
BMS and Pfizer Announce APPRAISE-1 Results for Apixaban II-69
Surface Logix Announces Encouraging Phase IIa Results of SLx-2101 II-70
Daiichi Sankyo Commences Phase III Clinical Trial for DU-176b II-70
New Clinical Data Demonstrates Effectiveness of Rasilez/
Tekturna in Obese Patients with Hypertension in Comparison to
Monotherapy with Diuretic Hydrochlorothiazide II-70
New Study Demonstrates Effectiveness of Exforge® in
Controlling High Blood Pressure in "difficult-to-treat"
Patients than Amlodipine Alone II-71
New Analyses Demonstrates Use of Cleviprex for Controlling
Perioperative Hypertension to Lower the Risk of Heart Attack
and Mortality Following Cardiac Surgery II-71
Observational Study Demonstrates Telmisartan to Provide
Powerful Blood Pressure Control for Complete 24-hours,
Including the Risky Hours of Early Morning II-71
New Study Demonstrates Tekturna® When Combined with Diovan® to
Have Additional Blood Pressure Lowering Effect II-72
Protherics Develops High Blood Pressure Vaccine II-72

7. RECENT INDUSTRY ACTIVITY II-73
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick II-73
Sanofi-aventis Takes Over Helvepharm II-73
Gilead Announces Agreement to Acquire CV Therapeutics II-73
Arca biopharma Merges with Nuvelo II-73
Merck Merges Business with Schering-Plough II-74
Zydus Cadila Joins Forces with Eli Lilly for Cardiovascular
Drug Research II-74
Actelion and GeneraMedix Sign Definitive Agreement II-74
AtCor Medical Enters into Contract with Pharmaceutical Company II-74
Daiichi Sankyo Sets Up Puerto Rican Subsidiary II-75
Wuzhou Pharma Secures Patent for Cardiovascular Drug II-75
Pfizer Completes Encysive Pharmaceuticals Acquisition II-75
Daiichi Sankyo Acquires Majority Interest in Ranbaxy II-75
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business II-76
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets II-76
Shionogi Acquires Sciele Pharma II-76
GlaxoSmithKline Acquires Reliant Pharmaceuticals II-77
Recordati Acquires Yeni Ilac II-77
Sinobiopharma Acquires DongYing Pharmaceutical II-77
Advent International Takes Over LaborMed Pharma II-78
Wyeth Pharmaceuticals Takes Over Thiakis Limited II-78
Jenson Services Acquires Majority Stake in LipidViro Tech II-78
King Pharmaceuticals to Acquire Alpharma II-78
China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical II-78
GlaxoSmithKline to Acquire Bristol-Myers Squibb Pakistan II-79
Meda Signs Deal to Take Over Roche Pharmaceutical Products II-79
Kyowa Hakko Merges with Kirin Pharma II-79
Belupo and Farmavita Announce Merger II-80
Cardiovascular Systems Merges with Replidyne II-80
Iroko Acquires Aggrastat’s Rights from Merck II-80
DAIICHI SANKYO ILAÇ Acquires Antihypertensive Drug, Concor II-80
PAION Announces Acquisition of Global Rights to Trigen’s
flovagatran II-80
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal II-81
Exelixis and Bristol-Myers Squibb Announce Collaboration II-81
Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive
Agreement II-81
Biological E Collaborates with Choncept and Heparinex II-82
Merck Extends Licensing Agreement with AstraZeneca II-82
Merck Serono Signs Distribution Agreement with Bristol-Myers
Squibb II-82
Quantum Genomics and PCAS Pharma Sign Strategic Agreement II-82
Forest Laboratories Holdings Amends Agreement with Mylan II-83
BMS and KAI Sign Pact to Develop, Commercialize Cardiovascular
Drug II-83
CV Therapeutics and Menarini Group Sign Deal for Ranexa II-83
VIA Pharma Signs Deal with Roche for Cardiovascular Drug
Candidates II-84
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements II-84
pSivida Signs Technology Evaluation Agreement for
Cardiovascular Drug Delivery II-85
Recordati Completes Mutual Recognition with 28 European Nations II-85
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion
Agreement II-85
Daiichi Sankyo Establishes Subsidiary in Ireland II-86
Kampala Pharma to Commence Production of High Blood Pressure
Drugs II-86
Daiichi Sankyo Submits Application for Antihypertensive Drug
Approval II-86
Zydus Cadila Submits IND Application for Cardiovascular Medicine II-86
Actelion and Merck Initiate Phase II Program Dosing, Reach
Fourth Milestone II-86
Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada II-87
Pharmaceutical Holdings Changes Name to URL Pharma II-87
Lupin Acquires Majority Interest in Kyowa Pharmaceutical II-87
Merck Acquires NovaCardia II-87
QuantRX Acquires Additional Stake in FluoroPharma II-88
SMI Products Acquires Nile Therapeutics II-88
Krka to Acquire German Company, TAD Pharma II-88
Private Group to Acquire Majority Stake in Inyx II-88
Jupiter Bioscience Acquires Drug Technology II-88
The Medicines Company Re-acquires European Rights for Angiox II-88
Sanofi-aventis Acquires Rights for Panaldine from Daiichi Sankyo II-89
Corautus Genetics and VIA Pharmaceuticals Sign Merger Agreement II-89
Cardiome and Eli-Lilly Ink Exclusive In-Licensing Deal II-89
Alchemia Inks Marketing Alliance with Dr. Reddy’s for Heparin II-90
Meda and Recordati Enter into Agreement for Zaneril® II-90
Meda and Recordati Sign Long-Term Agreement II-90
BMS and Pfizer Announce Collaboration for Apixaban II-91
BMS and Isis Announce Cardiovascular Disease Collaboration II-91
Vasogen Announces Collaboration with Grupo Ferrer Internacional II-91
Recordati- Berlin Chemie Expand Licensing Agreement II-92
Guangdong Luote Signs Agreement with Nippon Chemiphar II-92
Suven to Sign Cardiovascular Drugs Development Agreement with
US Firm II-92
Kaken to Commence Marketing Procylin for Pulmonary
Hypertension Treatment II-92
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets II-93
Biovail Reaches Settlement Agreement with Watson Pharmaceuticals II-93
Lexicon Genetics Announces Name Change II-93

8. PRODUCT INTRODUCTIONS II-94
Sanofi-aventis Wins FDA Approval for Multaq II-94
CV Therapeutics Introduces Ranexa® in Germany and the UK II-94
Takeda Introduces ECARD for Hypertension Treatment II-94
Amneal Pharmaceuticals Introduces Benazepril HCI II-95
Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in
India II-95
Gemini Pharmaceuticals Launches Antihypertensive Medicine,
Micardis II-95
Shionogi Introduces Fluitran® 1mg II-95
Helvepharm Launches New Antihypertensive Drug II-95
Ranbaxy Laboratories Introduces Amlodipine II-95
Nicholas Piramal Launches Hypertension Management Device II-96
GlaxoSmithKline Introduces Ambrisentan II-96
Novartis Introduces Aliskiren II-96
Dainippon Introduces Avapro for Hypertension Treatment II-96
Shionogi Introduces Irbetan for Hypertension Treatment II-96
Pfizer Japan Introduces Sildenafil II-97
Surgipharm Launches Diovan and Co-diovan II-97
King Pharmaceuticals Introduces Altace Tablets II-97
Encysive Pharmaceuticals Introduces Thelin Tablets II-97
Dr Reddy's Laboratories Introduces Atocor-R II-97
CV Therapeutics Rolls Out Ranexa® 1000 mg Tablet II-97
Wockhardt to Introduce Amlodipine Tablets II-98
GlaxoSmithKline Launches Coreg CR Extended-Release Capsules II-98
Toray and Astellas Introduce Careload LA Tablets II-98
AstraZeneca Introduces Crestor II-98
Torrent Pharma Introduces CVpill II-98
Ranbaxy Laboratories Introduces Generic Drug Verapamil II-99
Actavis Group Introduces NIFEdipine (XR) Tablets II-99
Apotex Introduces Norvasc Generic II-99
Novartis Introduces Aliskiren II-99
Encysive Introduces Sitaxentan in Ireland II-99
Pfizer to Release Generic Version of Norvasc II-99
Mylan Introduces Generic Blood Pressure Medicines II-100
Encysive Introduces Sitaxentan Encysive in Italy II-100
GlaxoSmithKline Introduces Carzec II-100
Encysive Pharmaceuticals Introduces Thelin in France II-100

9. PRODUCT APPROVALS II-101
Sanofi-aventis Wins FDA Approval for Multaq II-101
Astellas and Nippon Receive Approval for Micombi®
Antihypertensive Drug II-101
Daiichi Sankyo and Eli Lilly Win EC Approval for Efient® II-101
Novartis Wins FDA Approval for Tekturna HCT as Initial Therapy II-102
The Medicines Co Announces EU Acceptance of MAA for Cleviprex II-102
Ranbaxy Secures FDA Clearance for Ramipril Capsules II-102
Ranbaxy Receives FDA Approval for Antihypertensive Drug II-102
Sun Pharmaceuticals Receives Approval for Generic Version of
Accupril II-102
United Therapeutics Receives FDA Approval for PH Drug II-103
Novartis Obtains Approval from Japanese Health Ministry II-103
Novartis Obtains FDA Approval for Exforge HCT II-103
Novartis Obtains Approval for Four New Medicines II-103
Aveva Drug Delivery Obtains Approval for Clonidine TDS II-103
Actelion Wins FDA Approval for Tracleer® II-104
Ranbaxy Receives Canadian Approval to Market Anti-
Hypertension Drug II-104
Actelion Receives FDA Approval for New Ventavis Formulation II-104
Sinobiopharma Receives Chinese Approval for Perindopril II-104
Novartis Obtains FDA Approval for Tekturna HCT II-105
Lupin Receives FDA Approval for Generic Ramipril Capsules II-105
Abbott Secures FDA Approval for TriLipix II-105
Mylan Receives FDA Approval for Nisoldipine Extended-Release II-106
Glenmark Wins FDA Approval for Trandolapril II-106
CV Therapeutics Obtains FDA Approval for New Indication for
Ranexa II-106
Mylan Receives Tentative Approval for Generic Version of
Benicar HCT II-106
Novartis Secures Swissmedic Approval for Rasilez HCT II-107
Kyowa Secures Japanese Approval for Amlodipine Generic II-107
Novartis Obtains FDA Approval for Exforge and Diovan HCT II-107
CV Therapeutics Wins EMEA Approval for Brand Name, Ranexa II-107
Aurobindo Pharma Obtains FDA Approval II-108
Actelion Receives EU Approval for Tracleer II-108
The Medicines Company Wins FDA Approval for Cleviprex II-108
Indian Pharma Wins Approval for Propranolol Hydrochloride Tablets II-108
Aurobindo Pharma Secures FDA Approval for Lotensin Generic II-108
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril II-108
Mylan Wins FDA Approval for Mavik’s Generic II-109
Helpson Receives China FDA Approval to Market Bumetanide Generic II-109
Sciele Pharma Obtains FDA Approval II-109
Novartis’ Rasilez HCT Receives European Committee Recommendation II-109
Novartis Wins Canadian Approval for Rasilez II-109
Dr. Reddy's Receives FDA Approval for Trandolapril II-110
GeneraMedix Wins Approval from FDA for Epoprostenol II-110
Zydus Cadila Obtains FDA Approval for Ramipril Capsules II-110
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic II-110
Recordati Obtains Australian Approval for Zan-Extra® II-110
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs II-111
Boehringer Ingelheim Wins EU Commission Approval for
MicardisPlus® 80/25 II-111
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR® II-111
GlaxoSmithKline Wins EC Marketing Approval for Volibris II-111
BioInvent, ThromboGenics Receive Approval for Anticoagulant
Clinical Trials II-111
Novartis Secures FDA Approval for Exforge II-112
Bristol-Myers and Sanofi-aventis Obtain FDA Approval for Avalide II-112
Glenmark Wins FDA Approval for Coreg II-112
Sanofi-aventis Wins FDA Approval to Use Lovenox in STEMI Patients II-112
Daiichi Sankyo Wins FDA Approval for Azor II-112
Sanofi-aventis, BMS Win FDA Approval for Plavix 300mg II-113
Caraco Receives ANDA Approval for Norvasc Generic II-113
Mylan and Forest Labs Win FDA Approval to Market Bystolic II-113
Teva Bags Approval to Market Accupril Generic II-113
Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate II-114
Caraco Receives FDA Approval for Atenolol Tablets II-114
Novartis Wins Swissmedic Approval for Tekturna II-114
Lupin Bags Approval to Market Prinivil’s Generic Version II-114
Aurobindo Pharma Receives FDA Approval for Accuretic’s Generic
Version II-114
Gilead Sciences Wins FDA Approval for Letairis II-115
Wockhardt Wins FDA Approval to Market Lisinopril II-115
Pliva Wins FDA Approval for New Products II-115
Ranbaxy Wins Approval to Market Atenolol II-115
Ranbaxy Receives Health Canada Approval for Lisinopril Tablets II-115
Ranbaxy Receives Tentative Approval for Valsartan Tablets II-116
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER II-116
Ranbaxy Receives Approval from FDA for Coreg Generic II-116
KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic II-116
Encysive Pharma Wins Australian Approval for Thelin® II-117
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules II-117
Novartis Wins EU Approval for Rasilez II-117
GlaxoSmithKline Receives FDA Approval for Arixtra Injection II-117
GlaxoSmithKline Wins EMEA Approval for Arixtra II-118
GlaxoSmithKline Wins MHLW Approval for Arixtra II-118
Actavis Group Secures FDA Approval for Carvedilol Tablets II-118

10. FOCUS ON SELECT PLAYERS II-119
Abbott Laboratories Inc. (USA) II-119
AstraZeneca PLC (UK) II-119
Bayer AG (Germany) II-120
Biovail Corp. (Canada) II-120
Boehringer Ingelheim GmbH (Germany) II-120
Bristol-Myers Squibb Company (USA) II-121
Daiichi Sankyo Company, Ltd. (Japan) II-121
Forest Laboratories, Inc. (USA) II-122
GlaxoSmithKline PLC (UK) II-122
Merck & Co., Inc. (USA) II-123
Novartis AG (Switzerland) II-123
Pfizer, Inc. (USA) II-124
Sanofi-aventis (France) II-124
Solvay Pharmaceuticals SA (Belgium) II-125
Takeda Pharmaceutical Company Limited (Japan) II-125
The Medicines Company (USA) II-125

11. GLOBAL MARKET PERSPECTIVE II-126
Table 12: World Recent Past, Current & Future Analysis for
Cardiovascular Drugs by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, Latin America, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-126

Table 13: World Historic Review for Cardiovascular Drugs by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
Latin America, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2001 through 2006 (includes corresponding Graph/Chart) II-127

Table 14: World 13-Year Perspective for Cardiovascular Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for the US, Canada, Japan, Europe, Asia- Pacific, Latin
America, and Rest of World Markets for 2003, 2009 & 2015
(includes corresponding Graph/Chart) II-128

Table 15: World Recent Past, Current & Future Analysis for
Cardiovascular Drugs by Drug Class - Cholesterol Reducing
Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE
Inhibitors, Calcium Channel Blockers, Beta Blockers,
Anti-Arrhythmics, and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) II-129

Table 16: World 9-Year Perspective for Cardiovascular Drugs by
Drug Class - Percentage Breakdown of Dollar Sales for
Cholesterol Reducing Drugs, Angiotensin II Receptor Blockers,
Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers,
Beta Blockers, Anti-Arrhythmics, and Others Markets for 2007,
2009 & 2015 (includes corresponding Graph/Chart) II-130


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Cardiovascular Disease - Prevalence III-1
AHA Statistics for Cardiovascular Disease III-1
AHA Statistics for Coronary Heart Disease III-2
NCHS and NHLBI "Death Due to Cardiovascular Diseases" Data III-2
Market Overview III-2
Table 17: US Cardiovascular Drugs Market - Total
Prescriptions by Drug Class (in thousands): 2008 and 2009
(includes corresponding Graph/Chart) III-3

Table 18: Select Leading Myocardial Infarction Drugs in the
US: Value Sales for 2007 and 2008 in US$ Million (includes
corresponding Graph/Chart) III-4

Table 19: Select Leading Coronary Artery Disease/
Atherosclerosis Drugs in the US: Value Sales for 2007 and
2008 in US$ Million (includes corresponding Graph/Chart) III-4

Table 20: Select Leading Congestive Heart Failure Drugs in
the US: Value Sales for 2007 and 2008 in US$ Million
(includes corresponding Graph/Chart) III-5

Table 21: Select Leading Angina Drugs in the US: Value
Sales for 2007 and 2008 in US$ Million (includes
corresponding Graph/Chart) III-5
Antihypertensives III-6
Table 22: US Antihypertensive Drugs Market - Sales and
Percentage Share Breakdown by Leading Product in US$
Million Between October 2007 and October 2008 (includes
corresponding Graph/Chart) III-6
Prescription Trends III-7
Table 23: US Antihypertensive Drugs Market - Percentage
Share Breakdown of Total Prescriptions By Leading
Product: 2007 (includes corresponding Graph/Chart) III-7

Table 24: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Total Prescriptions by Leading Class
of Drug: 2007, 2008 and 2009 (includes corresponding
Graph/Chart) III-8

Table 25: US Antihypertensive Drugs Market - Percentage
Share Breakdown of ACE Inhibitors Based on Total
Prescriptions: 2007 (includes corresponding Graph/Chart) III-8

Table 26: US Antihypertensive Drugs Market - Percentage
Share Breakdown of Angiotension Receptor Antagonists
(ARAs) Based on Total Prescriptions: 2007 (includes
corresponding Graph/Chart) III-9
New Patient Therapy Starts to Witness Slowdown III-9
Table 27: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of Angiotensin II Receptor Antagonists in
terms of New Prescriptions for 2007, 2008 and 2009
(includes corresponding Graph/Chart) III-9

Table 28: US Anti-hypertensive Drugs Market - Percentage
Share Breakdown of ACE Inhibitors in terms of New
Prescriptions for 2007, 2008 and 2009 (includes
corresponding Graph/Chart) III-10

Table 29: US Anti-hypertensive Drugs market - Percentage
Share Breakdown of Calcium Channel Blockers in terms of
New Prescriptions for 2007, 2008 and 2009 (includes
corresponding Graph/Chart) III-11
African Americans At Major Health Risk Due to Hypertension III-11
Antihyperlipidemics III-12
Table 30: US Cardiovascular Drugs Market for Statins (HMG
CoA-Reductase Inhibitors) - Type of Statin Ranked by Value
Sales (in US$ Million): 2007 (includes corresponding
Graph/Chart) III-12

Table 31: US Cardiovascular Drugs Market for Fibrates
(Sales in US$ Million): 2007 III-13

Table 32: US Antihyperlipidemic Drugs Market - Percentage
Share Breakdown of Total Prescriptions by Leading Product:
2007 (includes corresponding Graph/Chart) III-13
Anticoagulants and Antiplatelets III-13
Table 33: US Anticoagulant Drugs Market - Percentage Share
Breakdown of Total Prescriptions by Leading Product: 2007
(includes corresponding Graph/Chart) III-13
Drug Development Pipeline III-14
Competitive Landscape III-14
Pharmaceutical III-14
Table 34: US Pharmaceutical Market - Leading
Pharmaceutical Companies Ranked by Value Sales (in US$
Million): 2008 (includes corresponding Graph/Chart) III-15

Table 35: US Pharmaceutical Market - Leading
Pharmaceutical Products Ranked by Value Sales (in US$
Million): 2007 (includes corresponding Graph/Chart) III-15

Table 36: US Pharmaceuticals Market - Leading Therapeutic
Class Ranked by Value Sales (in US$ Million): 2008
(includes corresponding Graph/Chart) III-16
Cardiovascular Drugs III-16
Table 37: US Cardiovascular Drugs Market - Leading
Companies Ranked by Cardiovascular Drug Sales (in US$
Million): 2008 (includes corresponding Graph/Chart) III-17
Research and Development III-17
Strategic Corporate Developments III-19
Product Launches III-29
Product Approvals III-31
Select Players III-42
B.Market Analytics III-46
Table 38: US Recent Past, Current & Future Analysis for
Cardiovascular Drugs by Drug Class - Cholesterol Reducing
Drugs, Angiotensin II Receptor Blockers, Anti-Thrombotics,
ACE Inhibitors, Calcium Channel Blockers, Beta Blockers,
Anti-Arrhythmics, and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) III-46

Table 39: US 13-Year Perspective for Cardiovascular Drugs by
Drug Class - Percentage Breakdown of Dollar Sales for
Cholesterol Reducing Drugs, Angiotensin II Receptor
Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel
Blockers, Beta Blockers, Anti-Arrhythmics, and Others
Markets for 2007, 2009 & 2015 (includes corresponding
Graph/Chart) III-47

Table 40: US Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-48

2. CANADA III-49
A.Market Analysis III-49
Current and Future Analysis III-49
Strategic Corporate Development III-49
Product Approvals III-49
B.Market Analytics III-50
Table 41: Canadian Recent Past, Current & Future Analysis
for Cardiovascular Drugs - Annual Sales Figures in US$
Million for Years 2007 through 2015 2006 (includes
corresponding Graph/Chart) III-50

Table 42: Canadian Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-51

3. JAPAN III-52
A.Market Analysis III-52
Current and Future Analysis III-52
Market Overview III-52
Research & Development III-52
Strategic Corporate Developments III-52
Product Launches III-54
Product Approvals III-55
Select Players III-57
B.Market Analytics III-58
Table 43: Japanese Recent Past, Current & Future Analysis
for Cardiovascular Drugs - Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-58

Table 44: Japanese Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-58

4. EUROPE III-59
A.Market Analysis III-59
Current and Future Analysis III-59
Cardiovascular Disease - Mortality Profile III-59
Cardiovascular Disease - Risk Factor Profile III-60
The Cardiovascular Disease Cost Burden III-60
EU to Face Health Care Expenditure Challenge Head-on III-60
Research & Development III-61
Strategic Corporate Developments III-63
Product Launches III-67
Product Approvals III-69
Select Players III-72
B.Market Analytics III-76
Table 45: European Recent Past, Current & Future Analysis
for Cardiovascular Drugs by Region - France, Germany, Italy,
United Kingdom, Spain, and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-76

Table 46: European Historic Review for Cardiovascular Drugs
by Region - France, Germany, Italy, United Kingdom, Spain,
and Rest of Europe Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-77

Table 47: European 13-Year Perspective for Cardiovascular
Drugs by Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, United Kingdom, Spain, and Rest of
Europe Markets for 2003, 2009 & 2015 (includes corresponding
Graph/Chart) III-78

Table 48: European Recent Past, Current & Future Analysis
for Cardiovascular Drugs by Drug Class - Cholesterol
Reducing Drugs, Angiotensin II Receptor Blockers,
Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers,
Beta Blockers, Anti-Arrhythmics, and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-79

Table 49: European 9-Year Perspective for Cardiovascular
Drugs by Drug Class- Percentage Breakdown of Dollar Sales
for Cholesterol Reducing Drugs, Angiotensin II Receptor
Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel
Blockers, Beta Blockers, Anti- Arrhythmics, and Others
Markets for 2007, 2009 & 2015 (includes corresponding
Graph/Chart) III-80

4a. FRANCE III-81
A.Market Analysis III-81
Current and Future Analysis III-81
B.Market Analytics III-81
Table 50: French Recent Past, Current & Future Analysis for
Cardiovascular Drugs - Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-81

Table 51: French Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-82

4b. GERMANY III-83
A.Market Analysis III-83
Current and Future Analysis III-83
B.Market Analytics III-83
Table 52: German Recent Past, Current & Future Analysis for
Cardiovascular Drugs - Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-83

Table 53: German Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-84

4c. ITALY III-85
A.Market Analysis III-85
Current and Future Analysis III-85
B.Market Analytics III-85
Table 54: Italian Recent Past, Current & Future Analysis for
Cardiovascular Drugs - Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-85

Table 55: Italian Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-86

4d. THE UNITED KINGDOM III-87
A.Market Analysis III-87
Current and Future Analysis III-87
B.Market Analytics III-87
Table 56: UK Recent Past, Current & Future Analysis for
Cardiovascular Drugs - Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-87

Table 57: UK Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-88

4e. SPAIN III-89
A.Market Analysis III-89
Current and Future Analysis III-89
B.Market Analytics III-89
Table 58: Spanish Recent Past, Current & Future Analysis for
Cardiovascular Drugs - Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) III-89

Table 59: Spanish Historic Review for Cardiovascular Drugs -
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) III-90

4f. REST OF EUROPE III-91
A.Market Analysis III-91
Current and Future Analysis III-91
B.Market Analytics III-91
Table 60: Rest of Europe Recent Past, Current & Future
Analysis for Cardiovascular Drugs - Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-91

Table 61: Rest of Europe Historic Review for Cardiovascular
Drugs - Annual Sales Figures in US$ Million for Years 2001
through 2006 (includes corresponding Graph/Chart) III-92

5. ASIA PACIFIC III-93
A.Market Analysis III-93
Current and Future Analysis III-93
Research & Development III-93
Strategic Corporate Developments III-94
Product Launches III-96
Product Approvals III-98
B.Market Analytics III-99
Table 62: Asia Pacific Recent Past, Current & Future
Analysis for Cardiovascular Drugs - Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-99

Table 63: Asia Pacific Historic Review for Cardiovascular
Drugs - Annual Sales Figures in US$ Million for Years 2001
through 2006 (includes corresponding Graph/Chart) III-100

6. LATIN AMERICA III-101
A.Market Analysis III-101
Current and Future Analysis III-101
Strategic Corporate Developments III-101
B.Market Analytics III-102
Table 64: Latin America Recent Past, Current & Future
Analysis for Cardiovascular Drugs - Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-102

Table 65: Latin America Historic Review for Cardiovascular
Drugs - Annual Sales Figures in US$ Million for Years 2001
through 2006 (includes corresponding Graph/Chart) III-102

7. REST OF WORLD III-103
A.Market Analysis III-103
Current and Future Analysis III-103
Strategic Corporate Developments III-103
Product Launches III-105
Product Approval III-106
B.Market Analytics III-106
Table 66: Rest of World Recent Past, Current & Future
Analysis for Cardiovascular Drugs - Annual Sales Figures in